PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma

The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the exp...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 14; no. 9155; p. 193
Main Authors Yu, Guanzhen, Yu, Wenlong, Jin, Guangzhi, Xu, Dongyun, Chen, Ying, Xia, Tian, Yu, Allan, Fang, Wenzheng, Zhang, Xiaoli, Li, Zhaosheng, Xie, Keping
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 14.11.2015
BioMed Central
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its impact on biology and clinical outcome of human HC. The regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival. We found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2 downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2 and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell proliferation and tumor growth. PKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an independent prognostic factor and potential therapeutic target for human HC.
AbstractList The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its impact on biology and clinical outcome of human HC. The regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival. We found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2 downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2 and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell proliferation and tumor growth. PKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an independent prognostic factor and potential therapeutic target for human HC.
The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its impact on biology and clinical outcome of human HC. The regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival. We found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2 downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2 and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell proliferation and tumor growth. PKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an independent prognostic factor and potential therapeutic target for human HC.
BACKGROUNDThe therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its impact on biology and clinical outcome of human HC.METHODSThe regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival.RESULTSWe found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2 downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2 and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell proliferation and tumor growth.CONCLUSIONSPKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an independent prognostic factor and potential therapeutic target for human HC.
Background The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its impact on biology and clinical outcome of human HC. Methods The regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival. Results We found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2 downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2 and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell proliferation and tumor growth. Conclusions PKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an independent prognostic factor and potential therapeutic target for human HC.
Background The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of cancers, while their roles in treatment of and prognosis for hilar cholangiocarcinoma (HC) remain unclear. In this study, we determined the expression of PKM2 in and its impact on biology and clinical outcome of human HC. Methods The regulation and function of PKM2 in HC pathogenesis was evaluated using human tissues, molecular and cell biology, and animal models, and its prognostic significance was determined according to its impact on patient survival. Results We found that expression of hexokinase 1 and the M2 splice isoform of PK (PKM2) was upregulated in HC tissues and that this expression correlated with tumor recurrence and outcome. PKM2 expression was increased in HC cases with chronic cholangitis as demonstrated by isobaric tags for relative and absolute quantification. High PKM2 expression was highly correlated with high syndecan 2 (SDC2) expression and neural invasion. PKM2 downregulation led to a decrease in SDC2 expression. Treatment with metformin markedly suppressed PKM2 and SDC2 expression at both the transcriptional and posttranscriptional levels and inhibited HC cell proliferation and tumor growth. Conclusions PKM2 regulates neural invasion of HC cells at least in part via regulation of SDC2. Inhibition of PKM2 and SDC2 expression contributes to the therapeutic effect of metformin on HC. Therefore, PKM2 is an independent prognostic factor and potential therapeutic target for human HC. Keywords: Prognosis, Metabolism, Biomarkers, PKM2, hilar cholangiocarcinoma
ArticleNumber 193
Audience Academic
Author Fang, Wenzheng
Jin, Guangzhi
Xie, Keping
Yu, Allan
Chen, Ying
Yu, Wenlong
Li, Zhaosheng
Zhang, Xiaoli
Xu, Dongyun
Xia, Tian
Yu, Guanzhen
Author_xml – sequence: 1
  givenname: Guanzhen
  surname: Yu
  fullname: Yu, Guanzhen
  email: qiaoshanqian@aliyun.com, qiaoshanqian@aliyun.com
  organization: Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. qiaoshanqian@aliyun.com
– sequence: 2
  givenname: Wenlong
  surname: Yu
  fullname: Yu, Wenlong
  organization: Department of Surgery, Eastern Hepatobiliary Hospital, Shanghai, People's Republic of China
– sequence: 3
  givenname: Guangzhi
  surname: Jin
  fullname: Jin, Guangzhi
  organization: Department of Pathology, Eastern Hepatobiliary Hospital, Shanghai, People's Republic of China
– sequence: 4
  givenname: Dongyun
  surname: Xu
  fullname: Xu, Dongyun
  organization: Department of Oncology, East Hospital, Tongji University School of Medicine, Shanghai, 200120, People's Republic of China
– sequence: 5
  givenname: Ying
  surname: Chen
  fullname: Chen, Ying
  organization: Department of Pathology, Changhai Hospital, Shanghai, People's Republic of China
– sequence: 6
  givenname: Tian
  surname: Xia
  fullname: Xia, Tian
  organization: Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
– sequence: 7
  givenname: Allan
  surname: Yu
  fullname: Yu, Allan
  organization: Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
– sequence: 8
  givenname: Wenzheng
  surname: Fang
  fullname: Fang, Wenzheng
  organization: Department of Oncology, East Hospital, Tongji University School of Medicine, Shanghai, 200120, People's Republic of China
– sequence: 9
  givenname: Xiaoli
  surname: Zhang
  fullname: Zhang, Xiaoli
  organization: Department of Pathology, Chinese People's Liberation Army, No 411 Hospital, Shanghai, People's Republic of China
– sequence: 10
  givenname: Zhaosheng
  surname: Li
  fullname: Li, Zhaosheng
  email: zhaoshenli.smmu.edu@hotmail.com
  organization: Department of Gastroenterology, Changhai Hospital, Shanghai, 200433, People's Republic of China. zhaoshenli.smmu.edu@hotmail.com
– sequence: 11
  givenname: Keping
  surname: Xie
  fullname: Xie, Keping
  email: kepxie@mdanderson.org
  organization: Department of Gastroenterology, Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. kepxie@mdanderson.org
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26576639$$D View this record in MEDLINE/PubMed
BookMark eNptUk1rFTEUDVKxH_oD3EjAjZup-Z7JRihFW7Gii-7jnUwyL2UmeSYzhf5783j10YokkNzknBPOzTlFRzFFh9BbSs4p7dTHQpkWvCFUNkQo1qgX6ISKVjVC6u7oyf4YnZZyRwhtu1a8QsdMyVYprk_Qr5_fvjOc3bhOsLiCo1szTDjEeyghRZw8hjjgbXZDsEvB25RyrdIYUwkF-1pt1hki3oQJMrabNEEcQ7KQbYhphtfopYepuDeP6xm6_fL59vK6uflx9fXy4qaxUpGl4X3PlAaqaC-1c4R46qnjwEBJKSnpe8m8aAfFusGCFsNAW-Cc8U733Gt-hj7tZbdrP7vBurhUH2abwwz5wSQI5vlNDBszpnsjlCSs41Xgw6NATr9XVxYzh2LdVO24tBZDWy41UUyKCn3_D_QurTlWdxXV6jplVTygRpicCdGn-q7diZoLITSr_aesos7_g6pjcHOw9bt9qOfPCHRPsDmVkp0_eKTE7FJh9qkwNRVmlwqjKufd0-YcGH9jwP8ALRG0Sg
CitedBy_id crossref_primary_10_1186_s13578_020_00463_7
crossref_primary_10_1016_j_phymed_2024_155775
crossref_primary_10_1101_cshperspect_a037044
crossref_primary_10_3389_fonc_2023_1285209
crossref_primary_10_1097_JS9_0000000000000795
crossref_primary_10_1007_s12072_022_10445_1
crossref_primary_10_18632_oncotarget_20693
crossref_primary_10_1016_j_clinre_2019_06_008
crossref_primary_10_1186_s12964_019_0332_8
crossref_primary_10_1038_s41388_019_0840_4
crossref_primary_10_18632_oncotarget_13703
crossref_primary_10_1038_s41598_017_14813_y
crossref_primary_10_1186_s12915_022_01340_0
crossref_primary_10_3389_fcell_2019_00355
crossref_primary_10_3389_fonc_2021_677678
crossref_primary_10_1097_MD_0000000000033232
crossref_primary_10_1007_s00432_019_02847_w
crossref_primary_10_1016_j_ejmech_2019_03_053
crossref_primary_10_3892_mmr_2022_12784
crossref_primary_10_3389_fonc_2022_874457
crossref_primary_10_1016_j_phymed_2023_154732
crossref_primary_10_1038_s41419_021_03990_4
crossref_primary_10_3892_br_2019_1188
crossref_primary_10_1097_HEP_0000000000000005
crossref_primary_10_3390_cancers14010018
crossref_primary_10_1002_iub_1678
crossref_primary_10_1002_path_5856
crossref_primary_10_1007_s11060_023_04521_1
crossref_primary_10_1016_j_gendis_2020_01_016
crossref_primary_10_3390_cells12151930
crossref_primary_10_3389_fphar_2023_1257450
crossref_primary_10_3892_ol_2018_7843
crossref_primary_10_1016_j_omto_2021_08_013
crossref_primary_10_1186_s12943_018_0791_3
crossref_primary_10_1002_wsbm_1406
crossref_primary_10_1007_s10620_023_08210_x
crossref_primary_10_1016_j_jhep_2022_04_038
crossref_primary_10_1186_s12885_018_4294_9
crossref_primary_10_1038_s41575_019_0217_8
crossref_primary_10_1007_s12253_019_00630_3
crossref_primary_10_1016_j_copbio_2017_03_022
crossref_primary_10_2174_0929867331666230714144851
crossref_primary_10_1016_j_tcb_2018_04_002
crossref_primary_10_1111_febs_16046
crossref_primary_10_18632_oncotarget_17377
crossref_primary_10_3390_cancers13020348
crossref_primary_10_1016_j_drudis_2024_103949
Cites_doi 10.1002/iub.1112
10.1172/JCI71104
10.1158/0008-5472.CAN-14-1952
10.1053/j.gastro.2014.04.048
10.18632/oncotarget.5772
10.1038/emm.2013.85
10.18632/oncotarget.3327
10.1074/jbc.M111.334730
10.1016/j.ccr.2013.06.014
10.1515/hsz-2013-0201
10.1186/1471-2407-13-343
10.1016/j.urolonc.2010.08.018
10.1007/s10238-013-0250-9
10.1016/j.ejphar.2013.02.038
10.1074/jbc.M202435200
10.1016/j.bbrc.2009.04.093
10.1158/1078-0432.CCR-13-2407
10.1016/j.semcdb.2012.02.003
10.18632/oncotarget.3983
10.1016/j.ygeno.2004.08.010
10.1016/j.febslet.2014.04.011
10.1158/0008-5472.CAN-11-3102
10.4161/cc.26461
10.1002/mc.10083
10.1016/j.bbrc.2005.02.189
10.1007/s12032-014-0015-7
10.1021/pr200482t
10.1016/j.jprot.2013.04.037
10.1016/j.jocn.2011.04.047
10.1016/j.bbrc.2011.04.135
10.1126/science.1160809
10.1016/j.ccr.2011.08.016
10.1016/j.dld.2012.08.012
10.1186/1756-9966-29-24
10.1007/s12253-013-9649-6
10.1007/s12094-013-1063-8
10.1007/s13277-013-1496-2
10.1038/onc.2012.181
10.1186/2047-783X-15-8-357
10.1016/j.prp.2013.06.005
10.1186/1476-4598-11-19
10.1038/sj.onc.1206068
ContentType Journal Article
Copyright COPYRIGHT 2015 BioMed Central Ltd.
Copyright BioMed Central 2015
Yu et al. 2015
Copyright_xml – notice: COPYRIGHT 2015 BioMed Central Ltd.
– notice: Copyright BioMed Central 2015
– notice: Yu et al. 2015
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1186/s12943-015-0462-6
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Complete (ProQuest Database)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 193
ExternalDocumentID 4016743871
A449266312
10_1186_s12943_015_0462_6
26576639
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GroupedDBID ---
-A0
0R~
123
29M
2WC
3V.
4.4
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
ECM
EIF
EJD
EMB
EMK
EMOBN
ESX
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
H13
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
CITATION
AFGXO
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c560t-3bb269a161b59ee00f1f1e3a2a655510bb52f47d628dca94dd17a332389b3f93
IEDL.DBID RPM
ISSN 1476-4598
IngestDate Tue Sep 17 21:27:50 EDT 2024
Sat Aug 17 02:19:08 EDT 2024
Thu Oct 10 18:30:15 EDT 2024
Wed Aug 14 18:53:53 EDT 2024
Tue Aug 13 05:21:28 EDT 2024
Thu Sep 12 20:00:18 EDT 2024
Sun Oct 13 09:39:10 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9155
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-3bb269a161b59ee00f1f1e3a2a655510bb52f47d628dca94dd17a332389b3f93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650283/
PMID 26576639
PQID 1779779528
PQPubID 42702
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4650283
proquest_miscellaneous_1735906254
proquest_journals_1779779528
gale_infotracmisc_A449266312
gale_infotracacademiconefile_A449266312
crossref_primary_10_1186_s12943_015_0462_6
pubmed_primary_26576639
PublicationCentury 2000
PublicationDate 2015-11-14
PublicationDateYYYYMMDD 2015-11-14
PublicationDate_xml – month: 11
  year: 2015
  text: 2015-11-14
  day: 14
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2015
Publisher BioMed Central Ltd
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
References L Jiang (462_CR10) 2013; 394
KC Soares (462_CR1) 2014; 3
C Marini (462_CR9) 2013; 12
J Chen (462_CR16) 2014; 35
MA Iqbal (462_CR11) 2014; 588
N Wong (462_CR12) 2014; 356
G Yu (462_CR35) 2015; 6
J Li (462_CR18) 2014; 16
DH Suh (462_CR17) 2013; 14
S Choi (462_CR30) 2009; 384
Z Zhu (462_CR21) 2002; 35
B Juntermanns (462_CR3) 2010; 15
KC Patra (462_CR8) 2013; 24
M Jang (462_CR14) 2013; 45
SJ Bensinger (462_CR5) 2012; 23
CV Rizos (462_CR34) 2013; 705
MA Pierotti (462_CR36) 2013; 32
Y Kim (462_CR26) 2003; 22
M Mytilinaiou (462_CR32) 2013; 65
K Wang (462_CR23) 2013; 13
H Chung (462_CR33) 2012; 287
X Zhang (462_CR19) 2013; 209
C Wang (462_CR25) 2012; 19
J Xue (462_CR37) 2014; 124
FZ Shen (462_CR15) 2010; 29
MD Pastor (462_CR20) 2013; 89
F Wang (462_CR24) 2013; 19
462_CR44
R Berardi (462_CR2) 2013; 45
X Huang (462_CR28) 2009; 21
462_CR45
C Huang (462_CR43) 2012; 72
H Lee (462_CR29) 2011; 409
T Oliveira De (462_CR22) 2012; 11
GZ Jin (462_CR39) 2011; 10
H Park (462_CR27) 2002; 277
W Fang (462_CR38) 2014; 31
N Zhang (462_CR42) 2011; 20
JW Huang (462_CR31) 2005; 330
MG Vander Heiden (462_CR6) 2009; 324
B Altenberg (462_CR7) 2004; 84
SJ Yun (462_CR13) 2012; 30
J Cui (462_CR41) 2014; 20
Y Chen (462_CR4) 2015; 6
L Li (462_CR40) 2014; 147
References_xml – volume: 65
  start-page: 134
  issue: 2
  year: 2013
  ident: 462_CR32
  publication-title: IUBMB Life
  doi: 10.1002/iub.1112
  contributor:
    fullname: M Mytilinaiou
– volume: 124
  start-page: 564
  issue: 2
  year: 2014
  ident: 462_CR37
  publication-title: J Clin Invest
  doi: 10.1172/JCI71104
  contributor:
    fullname: J Xue
– ident: 462_CR44
  doi: 10.1158/0008-5472.CAN-14-1952
– volume: 147
  start-page: 485
  issue: 2
  year: 2014
  ident: 462_CR40
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.04.048
  contributor:
    fullname: L Li
– ident: 462_CR45
  doi: 10.18632/oncotarget.5772
– volume: 45
  start-page: e45
  year: 2013
  ident: 462_CR14
  publication-title: Exp Mol Med
  doi: 10.1038/emm.2013.85
  contributor:
    fullname: M Jang
– volume: 6
  start-page: 12748
  issue: 14
  year: 2015
  ident: 462_CR35
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3327
  contributor:
    fullname: G Yu
– volume: 287
  start-page: 19326
  issue: 23
  year: 2012
  ident: 462_CR33
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.334730
  contributor:
    fullname: H Chung
– volume: 24
  start-page: 213
  issue: 2
  year: 2013
  ident: 462_CR8
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.06.014
  contributor:
    fullname: KC Patra
– volume: 21
  start-page: 1123
  issue: 4
  year: 2009
  ident: 462_CR28
  publication-title: Oncol Rep
  contributor:
    fullname: X Huang
– volume: 394
  start-page: 1333
  issue: 10
  year: 2013
  ident: 462_CR10
  publication-title: Biol Chem
  doi: 10.1515/hsz-2013-0201
  contributor:
    fullname: L Jiang
– volume: 3
  start-page: 18
  issue: 1
  year: 2014
  ident: 462_CR1
  publication-title: Hepatobil Surg Nutr
  contributor:
    fullname: KC Soares
– volume: 13
  start-page: 343
  year: 2013
  ident: 462_CR23
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-13-343
  contributor:
    fullname: K Wang
– volume: 30
  start-page: 893
  issue: 6
  year: 2012
  ident: 462_CR13
  publication-title: Urol Oncol
  doi: 10.1016/j.urolonc.2010.08.018
  contributor:
    fullname: SJ Yun
– volume: 14
  start-page: 345
  issue: 3
  year: 2013
  ident: 462_CR17
  publication-title: Clin Exp Med
  doi: 10.1007/s10238-013-0250-9
  contributor:
    fullname: DH Suh
– volume: 705
  start-page: 96
  issue: 1–3
  year: 2013
  ident: 462_CR34
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2013.02.038
  contributor:
    fullname: CV Rizos
– volume: 277
  start-page: 29730
  issue: 33
  year: 2002
  ident: 462_CR27
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M202435200
  contributor:
    fullname: H Park
– volume: 384
  start-page: 231
  issue: 2
  year: 2009
  ident: 462_CR30
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.04.093
  contributor:
    fullname: S Choi
– volume: 356
  start-page: 184
  issue: 2 Pt A
  year: 2014
  ident: 462_CR12
  publication-title: Cancer Lett
  contributor:
    fullname: N Wong
– volume: 20
  start-page: 2595
  issue: 10
  year: 2014
  ident: 462_CR41
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-2407
  contributor:
    fullname: J Cui
– volume: 23
  start-page: 352
  issue: 4
  year: 2012
  ident: 462_CR5
  publication-title: Semin Cell Dev Biol
  doi: 10.1016/j.semcdb.2012.02.003
  contributor:
    fullname: SJ Bensinger
– volume: 6
  start-page: 20419
  issue: 24
  year: 2015
  ident: 462_CR4
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3983
  contributor:
    fullname: Y Chen
– volume: 84
  start-page: 1014
  issue: 6
  year: 2004
  ident: 462_CR7
  publication-title: Genomics
  doi: 10.1016/j.ygeno.2004.08.010
  contributor:
    fullname: B Altenberg
– volume: 588
  start-page: 2685
  issue: 16
  year: 2014
  ident: 462_CR11
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2014.04.011
  contributor:
    fullname: MA Iqbal
– volume: 72
  start-page: 655
  issue: 3
  year: 2012
  ident: 462_CR43
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-3102
  contributor:
    fullname: C Huang
– volume: 12
  start-page: 3490
  issue: 22
  year: 2013
  ident: 462_CR9
  publication-title: Cell Cycle
  doi: 10.4161/cc.26461
  contributor:
    fullname: C Marini
– volume: 35
  start-page: 138
  issue: 3
  year: 2002
  ident: 462_CR21
  publication-title: Mol Carcinog
  doi: 10.1002/mc.10083
  contributor:
    fullname: Z Zhu
– volume: 330
  start-page: 1087
  issue: 4
  year: 2005
  ident: 462_CR31
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2005.02.189
  contributor:
    fullname: JW Huang
– volume: 31
  start-page: 15
  issue: 7
  year: 2014
  ident: 462_CR38
  publication-title: Med Oncol
  doi: 10.1007/s12032-014-0015-7
  contributor:
    fullname: W Fang
– volume: 10
  start-page: 3418
  issue: 8
  year: 2011
  ident: 462_CR39
  publication-title: J Proteome Res
  doi: 10.1021/pr200482t
  contributor:
    fullname: GZ Jin
– volume: 89
  start-page: 227
  year: 2013
  ident: 462_CR20
  publication-title: J Proteomics
  doi: 10.1016/j.jprot.2013.04.037
  contributor:
    fullname: MD Pastor
– volume: 19
  start-page: 541
  issue: 4
  year: 2012
  ident: 462_CR25
  publication-title: J Clin Neurosci
  doi: 10.1016/j.jocn.2011.04.047
  contributor:
    fullname: C Wang
– volume: 409
  start-page: 148
  issue: 1
  year: 2011
  ident: 462_CR29
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.04.135
  contributor:
    fullname: H Lee
– volume: 324
  start-page: 1029
  issue: 5930
  year: 2009
  ident: 462_CR6
  publication-title: Science
  doi: 10.1126/science.1160809
  contributor:
    fullname: MG Vander Heiden
– volume: 20
  start-page: 427
  issue: 4
  year: 2011
  ident: 462_CR42
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.08.016
  contributor:
    fullname: N Zhang
– volume: 45
  start-page: 70
  issue: 1
  year: 2013
  ident: 462_CR2
  publication-title: Dig Liver Dis
  doi: 10.1016/j.dld.2012.08.012
  contributor:
    fullname: R Berardi
– volume: 29
  start-page: 24
  year: 2010
  ident: 462_CR15
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/1756-9966-29-24
  contributor:
    fullname: FZ Shen
– volume: 19
  start-page: 815
  issue: 4
  year: 2013
  ident: 462_CR24
  publication-title: Pathol Oncol Res
  doi: 10.1007/s12253-013-9649-6
  contributor:
    fullname: F Wang
– volume: 16
  start-page: 200
  issue: 2
  year: 2014
  ident: 462_CR18
  publication-title: Clin Transl Oncol
  doi: 10.1007/s12094-013-1063-8
  contributor:
    fullname: J Li
– volume: 35
  start-page: 3743
  issue: 4
  year: 2014
  ident: 462_CR16
  publication-title: Tumour Biol
  doi: 10.1007/s13277-013-1496-2
  contributor:
    fullname: J Chen
– volume: 32
  start-page: 1475
  issue: 12
  year: 2013
  ident: 462_CR36
  publication-title: Oncogene
  doi: 10.1038/onc.2012.181
  contributor:
    fullname: MA Pierotti
– volume: 15
  start-page: 357
  issue: 8
  year: 2010
  ident: 462_CR3
  publication-title: Eur J Med Res
  doi: 10.1186/2047-783X-15-8-357
  contributor:
    fullname: B Juntermanns
– volume: 209
  start-page: 510
  issue: 8
  year: 2013
  ident: 462_CR19
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2013.06.005
  contributor:
    fullname: X Zhang
– volume: 11
  start-page: 19
  year: 2012
  ident: 462_CR22
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-11-19
  contributor:
    fullname: T Oliveira De
– volume: 22
  start-page: 826
  issue: 6
  year: 2003
  ident: 462_CR26
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206068
  contributor:
    fullname: Y Kim
SSID ssj0017874
Score 2.4351838
Snippet The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a variety of...
Background The therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a...
BACKGROUNDThe therapeutic and prognostic value of the glycolytic enzymes hexokinase, phosphofructokinase, and pyruvate kinase (PK) has been implicated in a...
SourceID pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 193
SubjectTerms Adult
Aged
Animals
Biological markers
Carrier Proteins - genetics
Carrier Proteins - metabolism
Cell Line, Tumor
Cell Proliferation - genetics
Cell Proliferation - physiology
Cells
Gene Expression Regulation, Neoplastic - genetics
Gene Expression Regulation, Neoplastic - physiology
Hexokinase - genetics
Hexokinase - metabolism
Humans
Klatskin Tumor - genetics
Klatskin Tumor - metabolism
Klatskin Tumor - pathology
Male
Membrane Proteins - genetics
Membrane Proteins - metabolism
Mice
Mice, Inbred BALB C
Middle Aged
Neoplasm Recurrence, Local - genetics
Neoplasm Recurrence, Local - metabolism
Neoplasm Recurrence, Local - pathology
Prognosis
Protein Isoforms - genetics
Protein Isoforms - metabolism
Syndecan-2 - genetics
Syndecan-2 - metabolism
Thyroid Hormone-Binding Proteins
Thyroid Hormones - genetics
Thyroid Hormones - metabolism
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFD_ohrIX0fmx6pQIgiCUNR9N2yeZY2ModwyZsLeYtI3rw9q79k7wv_ecNve6-rDnJCScnOT8Ts4v5wB88AjCa53T1y2vYmWliG2VUxpXxT3RLkpPjuLiTJ_-UF8v08vw4DYEWuX6Thwv6qor6Y38gGcZQpUiFfnn5U1MVaMouhpKaDyEbcEVhWm3vxyfnX_fxBFQHVWIZfJcHwxo3RTxh1KiNIpYz6zR_3fyHaM0J0zesUAnT-FJgI7scNrrZ_Cgbnfh0VRM8s8uPF6EMPlz-Hn-bSFYP5WZrwdGSStxZNP-tvQ4xjrPbFuxZU8jVgNbdl3PiKnVdkMzMMSxbKzdx64adHzZ6P-2vxo0ez1O0F3bF3BxcnxxdBqHUgpxiZBmFUvnhC4swjuXFnWdJJ57XksrrE4RMyXOpcKrrNIir0pbqKrimZUS7XnhpC_kS9hqu7beA5bbMpMi88KqUmW2cirXUqvEJ4mTkrsIPq0lapZTwgwzOhq5NpP4DYrfkPiNjuAjydzQYULBljb8CcCpKC2VOVSUz1BLLiLYn_XEQ1DOm9e7ZsIhHMw_lYng_aaZRhKxrK27W-ojU0rVnKoIXk2bvFm20OiMIYKLIJtt_6YDpeaet7TN1ZiiWyHwReD2-v5lvYEdQbpIrEK1D1ur_rZ-ixhn5d4FRf4LzS_7ig
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3da9RAEB9qRemLaP1otMoKgiBEk93JJnkQKWIpyokPLfRt3U2yNqDJmVzF_vfO5OO8k_q8O9kwM5v5bWb2NwAvPIHwSmd8dctjiFbJ0JYZ07hi7LnsovB8UFx81idn-PE8Od-Bub3VpMD-2qMd95M6676__v3z6h1t-LfDhs_0m55iFnJVUMKFijLUN-CmRIXs8Av8m1Qg38QpsXmtGBMDa8LfmjuHb0Spf7_VG8Fqu5ByIzId34U7E6QUR6MP3IOdqtmHW2OTyat9uL2Y0uf34euXTwspurH9fNULJrMkybr5ZfmnmWi9sE0plh1LrHqxbNtOcAVX0_Z1LwjfiqGnn7ioSWtiUF7zraZw2NEC7Q_7AE6PP5y-PwmnFgthQVBnFSrnpM4twT6X5FUVRT72caWstDohLBU5l0iPaallVhY2x7KMU6sUxfncKZ-rh7DbtE11ACKzRapk6qXFAlNbOsy00hj5KHJKxS6AV7NGzXIk0jDDASTTZrSEIUsYtoTRAbxknRs2Oym2sNNdAVqK6arMETLPoVaxDOBwayZtjmJ7eLaamX3LxGlKqDdPZBbA8_UwS3LBWVO1lzxHJUzhnGAAj0Yjr197dpIA0i3zrycwZff2SFNfDNTdSICYAN3j_z7zCexJ9kguNMRD2F11l9VTgj0r92xw5j_Yb_zp
  priority: 102
  providerName: Scholars Portal
Title PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/26576639
https://www.proquest.com/docview/1779779528
https://search.proquest.com/docview/1735906254
https://pubmed.ncbi.nlm.nih.gov/PMC4650283
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEB_uThRfRM-v6rlEEASht22Spu3jetxxrPRY9IR9q0nbeAW3Xdo9wf_emX4sWx99aR-SkJKZ6fwm-WUG4INFEF6oiK5uWelKLbir84jSuErfEu0isxQoJjfq-rtcroP1EQTjXZiOtJ-Z8rz6tTmvyruOW7ndZPORJzZfJRcSYQW6xfkxHIdCjCH6cHSAGiiH40s_UvMWHZokylBALEbuUs0irhBlK6oPfuCL_v0jH7ikKV3ywP9cPYUnA3Bki_4Dn8FRUZ3Cw76U5J9TeJQMh-TP4cfqS8JZ0xeZL1pGKStxZFn91rQ1xmrLdJWzbUMjdi3b1nXDiKdV1W3ZMkSxrKvcx-5KDHtZF_1WP0t0eg1OUG_0C7i9ury9uHaHQgpuhoBm5wpjuIo1gjsTxEXheda3fiE01ypAxOQZE3Arw1zxKM90LPPcD7UQ6M1jI2wsXsJJVVfFa2CRzkLBQ8u1zGSocyMjJZT0rOcZIXzjwKdxRdNtny4j7cKMSKW9JFKUREqSSJUDH2nNUzIlXNhMDzcCcCpKSpUuJGUzVMLnDpxNeqIJZNPmUWrpYIJt6ochYts44JED7_fNNJJoZVVR31MfEVCi5kA68KoX8v6zRyVxIJyIf9-BEnNPW1BfuwTdg36--e-Rb-ExJ40luqE8g5Ndc1-8Q_CzMzNU-XU4gweLxfLbEt-fL29WX2fdVgI-ExnNOnP4C_ghCOY
link.rule.ids 230,315,733,786,790,870,891,12083,21416,24346,27955,27956,31752,31753,33777,33778,43343,43838,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVjwuCMorUMBISEhIURPbcZITKqjVQrurCi1Sb8ZOYpoDyZJskfj3zCTepeHA2bZszYw939jjbwDeOAThlcro65aToTSCh6bMiMZVxo7SLgpHgeJiqeZf5eeL5MJfuPU-rXJ7Jg4HddkWdEd-GKcpQpU84dn79c-QqkbR66ovoXET9ohyM5vB3ofj5fmX3TsCmqP0b5lxpg579G6S8ocSSmnkoZp4o3_P5GtOaZowec0DndyHex46sqNR1w_gRtXsw62xmOTvfbi98M_kD-Hb-emCs24sM1_1jEgrcWTd_DJ0OcZax0xTsnVHIzY9W7dtxyhTq2n7umeIY9lQu49d1hj4siH-bb7X6PY6nKD9YR7B6uR49XEe-lIKYYGQZhMKa7nKDcI7m-RVFUUudnElDDcqQcwUWZtwJ9NS8awsTC7LMk6NEOjPcytcLh7DrGmb6imwzBSp4KnjRhYyNaWVmRJKRi6KrBCxDeDdVqJ6PRJm6CHQyJQexa9R_JrEr1UAb0nmmjYTCrYw_k8ATkW0VPpIEp-hEjEP4GDSEzdBMW3eak37TdjrvyYTwOtdM42kxLKmaq-oj0iIqjmRATwZlbxbNlcYjCGCCyCdqH_Xgai5py1NfTlQdEsEvgjcnv1_Wa_gzny1ONNnn5anz-EuJ7ukDEN5ALNNd1W9QLyzsS-9Uf8B2jH-gA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BERUXHuUVKGAkJCSk7Ca24yTHqrAqlK32UKSKi7GTmEbtJqvNLhL8embyWO322LNtOdHMZL6JP38D8MEhCC9UQle3nPSlEdw3eUIyrjJ0RLvIHBWK0zN18kN-u4gutlp9taT9zJaj6no-qsrLllu5mGfjgSc2nk2PJcIKTIvjRe7Gd-EexiyPh0K9P0BAP5T9IWaYqHGDaU0ScSgiLiP3qXMRV4i1FXUJ38pIN7_LW4lplzS5lYUmj-Dn8Pwd-eRqtF7ZUfbvhrTjrV7wMTzssSk76qY8gTtFdQD3u26Vfw9gf9qfwz-FX7PTKWfLro990TBSxcSVZfXH0N83VjtmqpwtlrRi1bBFXS8ZUcGquikbhkCZtc0B2WWJlTVrC-zqd4l5dYkb1HPzDM4nX86PT_y-V4OfIWZa-cJarlKD-NFGaVEEgQtdWAjDjYoQlAXWRtzJOFc8yTOTyjwPYyMEAobUCpeK57BX1VXxElhisljw2HEjMxmb3MpECSUDFwRWiNB68Gkwl150ihy6rWQSpTszazSzJjNr5cFHMqimaEWrZaa_dIBbke6VPpIkmKhEyD043JmJUZbtDg8uofsob3QYxwif04gnHrzfDNNKYq5VRb2mOSIiLehIevCi86DNYw8e6EG841ubCaT9vTuCHtNqgPce8urWK9_B_uzzRH__enb6Gh5wigwiN8pD2Fst18UbhFor-7YNqv8__yd8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PKM2+regulates+neural+invasion+of+and+predicts+poor+prognosis+for+human+hilar+cholangiocarcinoma&rft.jtitle=Molecular+cancer&rft.au=Yu%2C+Guanzhen&rft.au=Yu%2C+Wenlong&rft.au=Jin%2C+Guangzhi&rft.au=Xu%2C+Dongyun&rft.date=2015-11-14&rft.eissn=1476-4598&rft.volume=14&rft.spage=193&rft_id=info:doi/10.1186%2Fs12943-015-0462-6&rft_id=info%3Apmid%2F26576639&rft.externalDocID=26576639
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon